Table Of Contents
1. Market Context & Strategic Relevance
1.1 Opening Context (Why the market matters)
1.1.1 Why This Market Is Gaining Strategic Attention
1.1.2 Business Decisions This Report Supports
1.2 Scope
1.3 Research & Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035
2.3 Market Size & Forecast, By Segmentation, 2022–2035
2.3.1 Market Size By Device Type
2.3.2 Market Size By Insulin Type
2.3.3 Market Size By Treatment Type
2.3.4 Market Size By End User
2.3.5 Market Size By Distribution Channel
2.4 Market Share & Bps Analysis By Region, 2025
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Insulin Active Ingredient, Biosimilar Raw Material & Sensor Component Suppliers
3.4.2 Insulin, Pen, Pump & Glucose Monitor Manufacturers
3.4.3 Pharmacy Benefit Managers, Wholesalers, Retail & Online Pharmacies
3.4.4 Patients, Caregivers, Endocrinologists & Home Care Users
3.5 Industry Life Cycle Assessment
4. Statistical Insights & Trends Reporting
4.1 Disease Burden & Diagnosis Indicators
4.1.1 Global Type 1 Diabetes Patient Base
4.1.2 Pediatric & Adult Diagnosis Rates
4.1.3 Early Islet Autoantibody Screening Coverage
4.1.4 Diabetic Ketoacidosis at Diagnosis
4.2 Insulin Use & Access Metrics
4.2.1 Insulin Analog vs. Human Insulin Prescription Share
4.2.2 Biosimilar Insulin Uptake in Emerging Markets
4.2.3 Insulin Tender Volumes & Pricing
4.2.4 Out-of-Pocket Insulin Cost Trends
4.3 Device & Digital Care Adoption
4.3.1 Continuous Glucose Monitoring Use Across Age Groups
4.3.2 Automated Insulin Delivery System Uptake
4.3.3 Smart Pen & Connected Device Adoption
4.3.4 Telehealth & Remote Follow-Up Utilization
4.4 Clinical Outcomes & Therapy Innovation
4.4.1 Time in Range Improvement with Closed-Loop Systems
4.4.2 Severe Hypoglycemia Event Rates
4.4.3 Disease-Modifying Immunotherapy Uptake
4.4.4 Islet Cell Therapy Pipeline Progress
4.5 Reimbursement, Regulatory & Distribution Environment
4.5.1 Pump & Sensor Reimbursement Coverage by Region
4.5.2 Pediatric & Pregnancy Device Clearances
4.5.3 E-Pharmacy & Mail Order Dispensing Growth
4.5.4 Biosimilar Insulin Approval Trends
5. Type 1 Diabetes Market Segmental Analysis & Forecast, By Device Type, 2022–2035, Value (USD Billion)
5.1 Introduction
5.2 Insulin Pens
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2022–2035
5.3 Insulin Pumps
5.4 Insulin Syringes
5.5 Continuous Glucose Monitors
5.6 Others
6. Type 1 Diabetes Market Segmental Analysis & Forecast, By Insulin Type, 2022–2035, Value (USD Billion)
6.1 Introduction
6.2 Long-Acting Insulin
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2022–2035
6.3 Rapid-Acting Insulin
6.4 Short-Acting Insulin
6.5 Intermediate-Acting Insulin
6.6 Premixed Insulin
7. Type 1 Diabetes Market Segmental Analysis & Forecast, By Treatment Type, 2022–2035, Value (USD Billion)
7.1 Introduction
7.2 Insulin Therapy
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2022–2035
7.3 Automated Insulin Delivery Systems
7.4 Immunotherapy
7.5 Islet Cell Therapy
8. Type 1 Diabetes Market Segmental Analysis & Forecast, By End User, 2022–2035, Value (USD Billion)
8.1 Introduction
8.2 Home Care
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2022–2035
8.3 Hospitals and Clinics
8.4 Research Institutes
9. Type 1 Diabetes Market Segmental Analysis & Forecast, By Distribution Channel, 2022–2035, Value (USD Billion)
9.1 Introduction
9.2 Retail Pharmacies
9.2.1 Key Trends
9.2.2 Market Size & Forecast, 2022–2035
9.3 Online Pharmacies
9.4 Hospital Pharmacies
10. Type 1 Diabetes Market Segmental Analysis & Forecast By Region, 2022–2035, Value (USD Billion)
10.1 Introduction
10.2 North America
10.2.1 Key Trends
10.2.2 Type 1 Diabetes Market Size & Forecast, By Device Type, 2022–2035
10.2.3 Type 1 Diabetes Market Size & Forecast, By Insulin Type, 2022–2035
10.2.4 Type 1 Diabetes Market Size & Forecast, By Treatment Type, 2022–2035
10.2.5 Type 1 Diabetes Market Size & Forecast, By End User, 2022–2035
10.2.6 Type 1 Diabetes Market Size & Forecast, By Distribution Channel, 2022–2035
10.2.7 Type 1 Diabetes Market Size & Forecast, By Country, 2022–2035
10.2.7.1 USA
10.2.7.2 Canada
10.3 Europe
10.3.1 Key Trends
10.3.2 Type 1 Diabetes Market Size & Forecast, By Device Type, 2022–2035
10.3.3 Type 1 Diabetes Market Size & Forecast, By Insulin Type, 2022–2035
10.3.4 Type 1 Diabetes Market Size & Forecast, By Treatment Type, 2022–2035
10.3.5 Type 1 Diabetes Market Size & Forecast, By End User, 2022–2035
10.3.6 Type 1 Diabetes Market Size & Forecast, By Distribution Channel, 2022–2035
10.3.7 Type 1 Diabetes Market Size & Forecast, By Country, 2022–2035
10.3.7.1 Germany
10.3.7.2 UK
10.3.7.3 France
10.3.7.4 Italy
10.3.7.5 Spain
10.3.7.6 Russia
10.3.7.7 Poland
10.3.7.8 Rest of Europe
10.4 Asia-Pacific
10.4.1 Key Trends
10.4.2 Type 1 Diabetes Market Size & Forecast, By Device Type, 2022–2035
10.4.3 Type 1 Diabetes Market Size & Forecast, By Insulin Type, 2022–2035
10.4.4 Type 1 Diabetes Market Size & Forecast, By Treatment Type, 2022–2035
10.4.5 Type 1 Diabetes Market Size & Forecast, By End User, 2022–2035
10.4.6 Type 1 Diabetes Market Size & Forecast, By Distribution Channel, 2022–2035
10.4.7 Type 1 Diabetes Market Size & Forecast, By Country, 2022–2035
10.4.7.1 China
10.4.7.2 India
10.4.7.3 Japan
10.4.7.4 South Korea
10.4.7.5 Australia
10.4.7.6 ASEAN Countries
10.4.7.7 Rest of Asia-Pacific
10.5 Latin America
10.5.1 Key Trends
10.5.2 Type 1 Diabetes Market Size & Forecast, By Device Type, 2022–2035
10.5.3 Type 1 Diabetes Market Size & Forecast, By Insulin Type, 2022–2035
10.5.4 Type 1 Diabetes Market Size & Forecast, By Treatment Type, 2022–2035
10.5.5 Type 1 Diabetes Market Size & Forecast, By End User, 2022–2035
10.5.6 Type 1 Diabetes Market Size & Forecast, By Distribution Channel, 2022–2035
10.5.7 Type 1 Diabetes Market Size & Forecast, By Country, 2022–2035
10.5.7.1 Brazil
10.5.7.2 Argentina
10.5.7.3 Mexico
10.5.7.4 Colombia
10.5.7.5 Rest of Latin America
10.6 Middle East & Africa
10.6.1 Key Trends
10.6.2 Type 1 Diabetes Market Size & Forecast, By Device Type, 2022–2035
10.6.3 Type 1 Diabetes Market Size & Forecast, By Insulin Type, 2022–2035
10.6.4 Type 1 Diabetes Market Size & Forecast, By Treatment Type, 2022–2035
10.6.5 Type 1 Diabetes Market Size & Forecast, By End User, 2022–2035
10.6.6 Type 1 Diabetes Market Size & Forecast, By Distribution Channel, 2022–2035
10.6.7 Type 1 Diabetes Market Size & Forecast, By Country, 2022–2035
10.6.7.1 UAE
10.6.7.2 Saudi Arabia
10.6.7.3 Qatar
10.6.7.4 South Africa
10.6.7.5 Rest of Middle East & Africa
11. Competitive Landscape
11.1 Key Players' Positioning
11.2 Competitive Developments
11.2.1 Year-Wise Strategies & Development, 2022–2026
11.3 Market Share Analysis, 2025
11.4 Product/Service & Application Benchmarking
11.4.1 Product/Service Specifications & Features By Key Players
11.4.2 Product/Service Heatmap By Key Players
11.4.3 Application Heatmap By Key Players
11.5 Industry Start-Up & Innovation Landscape
11.6 Key Company Profiles
11.6.1 Novo Nordisk A/S
11.6.1.1 Company Overview & Snapshot
11.6.1.2 Product/Service Portfolio
11.6.1.3 Key Company Financials
11.6.1.4 Geographical Presence
11.6.1.5 SWOT Analysis
11.6.2 Eli Lilly and Company
11.6.3 Sanofi
11.6.4 Biocon Biologics
11.6.5 MiniMed Group, Inc. (formerly Medtronic Diabetes)
11.6.6 Dexcom, Inc.
11.6.7 Abbott Laboratories
11.6.8 Insulet Corporation
11.6.9 Tandem Diabetes Care, Inc.
11.6.10 Beta Bionics, Inc.
11.6.11 Sequel Med Tech
11.6.12 Senseonics Holdings, Inc.
11.6.13 mylife Diabetes Care
11.6.14 MannKind Corporation
11.6.15 Tonghua Dongbao Pharmaceutical Co., Ltd.
11.6.16 Gan & Lee Pharmaceuticals
11.6.17 Julphar (Gulf Pharmaceutical Industries)
11.6.18 Roche Diabetes Care (Accu-Chek)
12. Analyst Recommendations
12.1 SNS Insider Opportunity Map
12.2 Industry Low-Hanging Fruit Assessment
12.3 Market Entry & Growth Strategy
12.4 Analyst Viewpoint & Suggestions On Market Growth
13. Assumptions
14. Disclaimer
15. Appendix
15.1 List Of Tables
15.2 List Of Figures
Frequently Asked Questions
Key players include Novo Nordisk, Eli Lilly and Company, Sanofi, Biocon Biologics, MiniMed, Dexcom, Abbott, Insulet, Tandem Diabetes Care, Beta Bionics, Sequel Med Tech, Senseonics, mylife Diabetes Care, MannKind, Tonghua Dongbao, Gan & Lee Pharmaceuticals, Julphar and Roche Diabetes Care.
Key opportunities include disease-modifying immunotherapy, islet cell therapy, early autoantibody screening, closed-loop insulin delivery and insulin biosimilars in emerging markets.
Rising diagnosed prevalence and the adoption of continuous glucose monitoring and automated insulin delivery are the main growth factors.
By Device Type, the Insulin Pens segment dominated the market in 2025 with an estimated 46.65% share, supported by ease of use, accurate dosing and wide availability.
North America dominated the market with a share of 41.53% in 2025, driven by early technology adoption, high diagnosis rates and broad insurance coverage.
